GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alkermes PLC (NAS:ALKS) » Definitions » Shiller PE Ratio

Alkermes (Alkermes) Shiller PE Ratio : (As of May. 19, 2024)


View and export this data going back to 1991. Start your Free Trial

What is Alkermes Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Alkermes Shiller PE Ratio Historical Data

The historical data trend for Alkermes's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alkermes Shiller PE Ratio Chart

Alkermes Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Alkermes Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Alkermes's Shiller PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Alkermes's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alkermes's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Alkermes's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Alkermes's Shiller PE Ratio falls into.



Alkermes Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Alkermes's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Alkermes's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.21/120.9901*120.9901
=0.210

Current CPI (Mar. 2024) = 120.9901.

Alkermes Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 0.020 100.773 0.024
201409 -0.270 100.474 -0.325
201412 0.200 99.576 0.243
201503 -0.210 99.975 -0.254
201506 -0.310 100.573 -0.373
201509 -0.540 100.274 -0.652
201512 -0.460 99.676 -0.558
201603 -0.510 99.676 -0.619
201606 -0.310 101.072 -0.371
201609 -0.410 100.274 -0.495
201612 -0.140 99.676 -0.170
201703 -0.450 100.374 -0.542
201706 -0.280 100.673 -0.337
201709 -0.240 100.474 -0.289
201712 -0.060 100.075 -0.073
201803 -0.400 100.573 -0.481
201806 -0.210 101.072 -0.251
201809 -0.220 101.371 -0.263
201812 -0.060 100.773 -0.072
201903 -0.620 101.670 -0.738
201906 -0.270 102.168 -0.320
201909 -0.340 102.268 -0.402
201912 -0.030 102.068 -0.036
202003 -0.240 102.367 -0.284
202006 -0.190 101.769 -0.226
202009 -0.001 101.072 -0.001
202012 -0.270 101.072 -0.323
202103 -0.140 102.367 -0.165
202106 0.010 103.364 0.012
202109 -0.180 104.859 -0.208
202112 0.010 106.653 0.011
202203 -0.220 109.245 -0.244
202206 -0.180 112.779 -0.193
202209 -0.390 113.504 -0.416
202212 -0.170 115.436 -0.178
202303 -0.250 117.609 -0.257
202306 1.380 119.662 1.395
202309 0.280 120.749 0.281
202312 0.660 120.749 0.661
202403 0.210 120.990 0.210

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Alkermes  (NAS:ALKS) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Alkermes Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Alkermes's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Alkermes (Alkermes) Business Description

Traded in Other Exchanges
Address
1 Burlington Road, Connaught House, Dublin, IRL, D04 C5Y6
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several collaborative arrangements to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies.
Executives
Cato T Laurencin director C/O UNIVERSITY OF CONNECTICUT, 263 FARMINGTON AVENUE, FARMINGTON CT 06030-3800
Christian Todd Nichols officer: SVP, Chief Commercial Officer 852 WINTER STREET, WALTHAM MA 02451
Nancy Wysenski director 2200 SUNBURST STREET, CHATSWORTH CA 90401
Daglio David Angelo Jr. director ALKERMES, 852 WINTER STREET, WALTHAM MA 02451
Christopher I Wright director C/O CYCLERION THERAPEUTICS, INC., 245 FIRST STREET, 18TH FLOOR, CAMBRIDGE MA 02142
Michael J Landine officer: SVP, Corp Dev., Alkermes, Inc. 88 SIDNEY ST, CAMBRIDGE MA 021394136
Richard F Pops director, officer: Director and CEO, Alkermes plc 10555 SCIENCE CENTER DR, SAN DIEGO CA 92121
Shane Cooke officer: President, Alkermes plc TREASURY BUILDING LOWER GRAND CANAL ST., DUBLIN 2 L2 00000
Blair Curtis Jackson officer: EVP, Chief Operating Officer 852 WINTER STREET, WALTHAM MA 02451
Snyderman Nancy Lynn Md director 37 PHEASANT HILL ROAD, PRINCETON NJ 08540
Craig C. Hopkinson officer: SVP, Med Dev/Med Affairs, CMO 852 WINTER STREET, WALTHAM MA 02451
Emily Peterson Alva director C/O AMNEAL PHARMACEUTICALS LLC, 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807
Iain Michael Brown officer: VP, Finance & CAO 14 ROYALSTON AVENUE, WINCHESTER MA 01890
Brian P Mckeon director IDEXX LABORATORIES, ONE IDEXX DRIVE, WESTBROOK ME 04092
David Joseph Gaffin officer: SVP, CLO, Alkermes, Inc. 852 WINTER STREET, WALTHAM MA 02451